常規時段
					
										
  | 
									
										
  | 
									
										
  | 
									
										
  | 	
										
										
  | 
									
									
									
								||||||||||||
  | 
									
										
  | 
								
									
										
  | 
									
										
  | 
									
										
  | 
								
										
  | 
									
										
  | 
									
										
  | 
								
| 價值評估 | 
| 
										 盈利(現時/預測) 
										
												-1.78/-1.29										 
									 | 
								
| 
										 企業價值 
										
											250.42M										 
									 | 
								
| 資產負債 | 
| 
											 每股賬面淨值 
											
												1.78											 
										 | 
									
| 現金流量 | 
| 
											 現金流量率 	
											
																					--											 
										 | 
									
| 損益表 | 
| 
											 收益 
											 
													9.99M											 
										 | 
									
| 
											 每股收益 
											
												0.37											 
										 | 
									
| 
	   					 同行比較 
	   					
	   				 | 
	   			||||||||||||||||||||||||||||||||||||||||||||||||
  | 
		   		
 
																報價延遲最少15分鐘:2025/11/04 02:22 EST
																				
						同行比較之報價最少15分鐘延遲
											| 
						 業務概覽 
					 | 
				|||
| Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPRplatform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipelineof allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue. | 

				
						
 2.43														
